Clinical Trials on mCRC

Total 178 results

Dr.Laurent Mineur
Merck Serono International SA; BESPIM, CHU Nîmes (data analysis)

Unknown

PREMIUM, Observational Study

First Line WT KRAS mCRC

France
Amgen

Completed

Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wild-type.PERSEIDA Study (PERSEIDA)

RAS Wild Type mCRC

Spain
Impact Therapeutics, Inc.

Not yet recruiting

Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment

mCRPC

Australia, United States, China
AstraZeneca

Completed

Determination of Prevalence and Features of HRRm mCRPC (ADAM) (ADAM)

HRRm mCRPC

Russian Federation
Motus GI Medical Technologies Ltd

Terminated

Evaluation of Bowel Cleansing Using the Pure-Vu System in Patients With History of Inadequate Bowel Preparation

CRC

Israel
Shanghai Henlius Biotech

Not yet recruiting

Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC

CRC
Motus GI Medical Technologies Ltd

Completed

Evaluation of the Performance of the Motus Cleansing System (MCS) (MCS)

CRC

Netherlands, Germany
Motus GI Medical Technologies Ltd

Completed

Evaluation of the Motus GI CleanUp System During Screening Colonoscopy

CRC
Chinese University of Hong Kong

Withdrawn

Effect of WhatsApp Messenger on Uptake of CRC Screening Study

CRC

Hong Kong
Motus GI Medical Technologies Ltd

Completed

Clinical Investigational Plan: Evaluation of the Performance of the Motus Cleansing System

CRC

Israel
Motus GI Medical Technologies Ltd

Completed

Evaluation of the Motus Gl CleanUp System During Screening Colonoscopy

CRC

Spain
The Netherlands Cancer Institute
Erasmus Medical Center; Amsterdam University Medical Centres (AUMC)

Active, not recruiting

Prospective Clinical Validation of a Novel Multitarget FIT in CRC Screening (mtFIT)

CRC | Advanced Neoplasia

Netherlands
Chinese University of Hong Kong

Completed

Lay Tel Compliance Study

Compliance, Patient | CRC Screening

Hong Kong
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

FIH Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation in China

NSCLC | Solid Tumor | CRC

China
Istituto Scientifico Romagnolo per lo Studio e...

Recruiting

Investigation of PSMA PET/CT as an Imaging Biomarker in Solid Tumors (BASKET PSMA)

Prostate-specific Membrane Antigen | mCRPC or Advanced/Metastatic Solid Tumors

Italy
jianming xu
KAEDI

Recruiting

NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors

Solid Tumor | CRC

China
Niguarda Hospital
University of Turin, Italy; Fondazione del Piemonte per l'Oncologia

Completed

Donation of Post Mortem Tumor Tissues (DONUM)

NSCLC Stage IV | CRC | CUP

Italy
SparX Biotech(Jiangsu) Co., Ltd.

Recruiting

A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors (SPX-303)

Solid Tumor | CRC | HNSCC | RCC

United States
InventisBio Co., Ltd
Merck Sharp & Dohme LLC

Active, not recruiting

Study to Evaluate D-1553 in Subjects With Solid Tumors

NSCLC | Solid Tumor, Adult | CRC

United States, Taiwan, Australia, Korea, Republic of
Zenith Epigenetics

Enrolling by invitation

Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol

mCRPC

United States
Peking University
Zhejiang University; Liaoning Tumor Hospital & Institute

Active, not recruiting

Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer

mCRC

China
Letolab

Not yet recruiting

Phase II Clinical Study of LTC004 in Patients With mCRC

Locally Advanced or Metastatic CRC
Pfizer
Astellas Pharma Inc

Active, not recruiting

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC (TALAPRO-2)

mCRPC

China, Finland, Spain, United States, Hungary, Israel, Belgium, Korea, Republic of, France, Canada, Czechia, Australia, Japan, Brazil, Germany, Argentina, New Zealand, United Kingdom, Norway, South Africa, Poland, Portugal, Chile, Italy, Pe... and more
Shanghai JMT-Bio Inc.

Not yet recruiting

A Study of JMT101 in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer (mCRC)
Sun Yat-sen University
Hutchmed; BeiGene

Not yet recruiting

Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer

Metastatic Colorectal Cancer | mCRC

China
Shanghai Henlius Biotech

Active, not recruiting

The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation

Metastatic Colorectal Cancer | mCRC

China
Bristol-Myers Squibb

Completed

A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer (mCRC)

United States
ImmunityBio, Inc.

Active, not recruiting

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

Colorectal Cancer Metastatic | mCRC

United States
mAbxience Research S.L.
Laboratorio Elea Phoenix S.A.; Libbs Farmacêutica LTDA

Completed

Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients

Metastatic Colorectal Cancer (mCRC)

Argentina, Brazil, India, Spain, Ukraine
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

NSCLC | Advanced Solid Tumor | CRC

United States
Institut du Cancer de Montpellier - Val d'Aurelle

Recruiting

Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients (NEXT-REGIRI)

Metastatic Colorectal Cancer (mCRC)

France
Shanghai Henlius Biotech

Active, not recruiting

A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC

Metastatic Colorectal Cancer (mCRC)

China
Terumo Europe N.V.
Universitaire Ziekenhuizen KU Leuven; Federation Francophone de Cancerologie...

Completed

LifePearl-Iri Pharmacokinetic Study

Metastatic Colorectal Cancer | mCRC

Belgium, Germany
Tianjin Medical University Cancer Institute and...

Recruiting

Efficacy and Safety of Sintilimab Combined With Regorafenib and Cetuximab / Sintilimab Combined With Regorafenib in Posterior Line Therapy of Advanced Colorectal Cancer (Regosinti)

Sintilimab, Cetuximab, Regorafenib,Combine,mCRC

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC

Metastatic Colorectal Cancer (mCRC)

China
Bayer

Active, not recruiting

An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions (STAR-T)

Metastatic Colorectal Cancer (mCRC)

United States
Bristol-Myers Squibb

Completed

Phase I/II Combination With Irinotecan- Erbitux

Metastatic Colorectal Cancer (MCRC)

United States, Italy, Korea, Republic of, Spain, Sweden, Argentina, Denmark
Calithera Biosciences, Inc

Completed

A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

NSCLC | Solid Tumors | KRAS Gene Mutation | CRC

United States
Medtronic - MITG

Completed

Evaluation of Capsule Endoscopy With PillCam® COLON 2 in Visualization of the Colon

CRC Screening

United States, Israel
Holy Stone Healthcare Co., Ltd

Temporarily not available

Individual Patient Expanded Access to CA102N

Advanced or Metastatic Colorectal Cancer (mCRC)
Lipomedix Pharmaceuticals Inc.

Completed

Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.

Cancer | Solid Tumor | Metastatic Colorectal Cancer (mCRC)

Israel
Holy Stone Healthcare Co., Ltd

Completed

First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors

Advanced or Metastatic Solid Tumors | Advanced or Metastatic Colorectal Cancer (mCRC)

United States
Harbin Medical University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC

HCC | NSCLC | CRC
Cancer Institute and Hospital, Chinese Academy...

Recruiting

XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC

Bevacizumab | Capecitabine | Metastatic Colorectal Cancer (mCRC) | Oxaliplatin | Tislelizumab | First-Line | MSS/pMMR | RAS-mutated

China
Genentech, Inc.

Recruiting

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough

Chronic Refractory Cough (CRC) With Non-atopic Asthma | CRC With Atopic Asthma | Unexplained Chronic Cough | CRC With Chronic Obstructive Pulmonary Disease | CRC With Chronic Obstructive Pulmonary Disease With Chronic Bronchitis

United States, Australia, United Kingdom, Canada
Zhejiang Cancer Hospital

Not yet recruiting

Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC

Metastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRC

China
AstraZeneca

Completed

A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

Advanced Solid Malignancies | Non-Small Cell Lung Cancer (NSCLC) | Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC) | Colorectal Carcinoma (CRC)

United States
Erasmus Medical Center
University of Calgary; Institute of Tropical Medicine; Indonesia University; Utrecht... and other collaborators

Not yet recruiting

Impact of Reducing Colistin Use on Colistin Resistance in Humans and Poultry in Indonesia (COINCIDE)

Antimicrobial Resistance | Colonization, Asymptomatic | Colistin | Mcr-1

Indonesia
Bayer

Completed

Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo). (PHENIX)

Metastatic Castration-resistant Prostate Cancer (mCRPC)

United States
FutureChem

Recruiting

[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2 (LUCIDA_2)

Metastatic Castration-resistant Prostate Cancer, mCRPC

Korea, Republic of

Clinical Trials on mCRC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations